FindTrial
Sign In

Plasmapheresis for the treatment of severe pemphigus: a prospective study

Plasmapheresis for the treatment of severe pemphigus: a prospective study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046813
Enrollment
Unknown
Registered
2021-05-28
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus

Interventions

Plasmapheresis group:Plasmapheresis
Conventional therapy group:Nil

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 65 years; 2. Definitive diagnosis as pemphigus: (1) Typical clinical manifestation; (2) Typical histopathological features; (3) Typical direct and indirect immunofluorescence manifestations; (4) Positive serum Dsg antibody; 3. Severe clinical symptoms. PDAI>24; 4. Voluntary participation, and can sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. There is contraindication for central venous catheterization; 2. Vital signs are unstable; 3. Pregnant women.

Design outcomes

Primary

MeasureTime frame
Pemphigus disease area index;—

Secondary

MeasureTime frame
Duration for remission;The titers of Dsg antibody;All-cause death;Cumulative dose of steroids;—

Countries

China

Contacts

Public ContactLiu Yan

Peking Union Medical College Hospital

liuyanpumch@163.com+86 18611690815

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026